Release Date: August 2008; Expiration Date: August 31, 2009

Chair Timothy E. Wilens, MD Associate Professor, Psychiatry Harvard Medical School Director of Substance Abuse Services Pediatric Psychopharmacology Research Program Massachusetts General Hospital Boston, Massachusetts

Click on the name of a faculty member to view full biography below, and click once more to close biography.

Distinguished Faculty

Birgit H. Amann, MD Associate Medical Director Rochester Center for Behavioral Medicine Rochester Hills, Michigan

Joseph Biederman, MD Professor, Psychiatry Harvard Medical School Chief, Clinical and Research Programs Pediatric Psychopharmacology and Adult ADHD Massachusetts General Hospital Boston, Massachusetts

James T. McCracken, MD Director, Child and Adolescent Psychiatry UCLA Neuropsychiatric Institute and Hospital Los Angeles, California

Anthony L. Rostain, MD, MA Professor, Psychiatry and Pediatrics Director of Education, Department of Psychiatry University of Pennsylvania Health System Philadelphia, Pennsylvania This activity was developed in cooperation with (Larry Culpepper, MD, MPH)

Larry Culpepper, MD, MPH Professor and Chair, Family Medicine Boston University School of Medicine Chief, Family Medicine Boston Medical Center Boston, Massachusetts

Sponsored by Veritas Institute for Medical Education, Inc.
Supported by an educational grant from McNeil Pediatrics, administered by Ortho-McNeil Janssen Scientific Affairs, LLC

Target Audience
Psychiatrists, primary care physicians, and nurse practitioners involved in the treatment of patients with ADHD

Learning Objectives
Module 1: Focus on Diagnosis
Estimated time to complete: 15 minutes

1. You will be better able to diagnose ADHD and differentiate it from common psychiatric comorbidities.
2. You will be able to explain the impairments and impact of untreated ADHD on adolescent and adult patients and the importance of treating the disorder.

Module 2: Focus on Treatment
Estimated time to complete: 30 minutes

1. You will be able to develop a multimodal treatment plan tailored to the individual patient, which may include medication, psychosocial treatment, organizational training, education, and accommodations in school and at work.
2. You will be able to select and titrate pharmacologic treatments that improve symptomatic behavior and cognitive functioning in adolescents and adults with ADHD.

Module 3: Applying Knowledge to Patient Care: A Video Case Study
Estimated time to complete: 15 minutes

1. You will be better able to diagnose ADHD and differentiate it from common psychiatric comorbidities.


2. You will be able to select and titrate pharmacologic treatments that improve symptomatic behavior and cognitive functioning in adolescents and adults with ADHD.

Method of Participation
In order to receive credit for these activities, participants must:

1. View/complete each module.
2. Complete and submit the CME/CE Activity Evaluation and Request for Credit Form.
3. Print the CME certificate or nursing statement of credit.

These activities are provided free of charge.

Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians
Module 1: Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits^TM.
Module 2: Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credits^TM.
Module 3: Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits^TM.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Family Physicians
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Nurse Practitioners
Veritas Institute for Medical Education, Inc. approved as a provider for nurse practitioner continuing education by the American Academy of Nurse Practitioners: AANP Provider Number 040309.
Module 1
This program has been approved for a combined maximum of up to 0.25 contact hour of continuing education (which includes 0.25 hour of pharmacology).
Module 2
This program has been approved fo a combined maximum of up to 0.50 contact hour of continuing education (which includes 0.25 hour of pharmacology).
Module 3
This program has been approved for a combined maximum of up to 0.25 contact hour of continuing education (which includes 0.25 hour of pharmacology).

Financial Disclosure Statements
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Disclosures are as follows:

Birgit H. Amann, MD―Eli Lilly and Company, Ortho-McNeil Janssen Scientific Affairs, LLC., Novartis Pharmaceuticals Corporation, Shire, UCB Pharma, Inc (speakers bureau).

Joseph Biederman, MD―Alza, Bristol-Myers Squibb, Eli Lilly and Company, Merck and Co., Inc., National Institute of Mental Health, NICHD, Novartis Pharmaceuticals Corporation, Ortho-McNeil Janssen Scientific Affairs, LLC., Otsuka, Shire, and UCB Pharma Inc. (advisory board, consultant, grant/research support, and/or speakers bureau)

Larry Culpepper, MD, MPH―AstraZeneca, Blue Cross Foundation of Massachusetts; Forest Laboratories, Eli Lilly and Company, Neurocrine Biosciences, Pfizer, Wyeth (consultant and advisory boards, research, and/or speakers bureau)

James T. McCracken, MD―Bristol-Myers Squibb, Eli Lilly and Company, Pfizer Inc, Novartis Pharmaceuticals Corporation, Ortho-McNeil Janssen Scientific Affairs, LLC., Shire, UCB Pharma Inc, Wyeth (advisory board, consultant, grant/research support, and/or speakers bureau)

Anthony L. Rostain, MD, MA―Eli Lilly and Company, Ortho-McNeil Janssen Scientific Affairs, LLC., Shire (speakers bureau and/or advisory board).

Timothy E. Wilens, MD―Abbott Laboratories, Cephalon Inc, Eli Lilly and Company, Merck and Co., Inc., National Institute of Mental Health, National Institute on Drug Abuse, Novartis Pharmaceuticals Corporation, Ortho-McNeil Janssen Scientific Affairs, LLC., Shire. (consultant, grant/research support, and/or speakers bureau)

The staff of Veritas Institute for Medical Education, Inc., has nothing to disclose.

Disclaimer
The opinions expressed in this activity are those of the presenters and do not necessarily reflect those of Veritas Institute for Medical Education, Inc., or McNeil Pediatrics, administered by Ortho-McNeil Janssen Scientific Affairs, LLC. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.

OFF-LABEL/INVESTIGATIONAL USES OF DRUGS/MEDICAL DEVICES DISCLOSURE
Participants are advised that this CME/CE activity will contain references to unlabeled/unapproved/investigational uses of drugs to treat patients with ADHD.

Program Overview
Attention-deficit/hyperactivity disorder (ADHD) remains an undertreated and underrecognized disorder. Studies have shown that fewer than half of all children and adolescents who met DSM-IV criteria for ADHD had had a prior diagnosis, and fewer than a third of these had received medication for ADHD for most of the previous 12 months. Among adults, the situation is even worse, as the National Comorbidity Survey Replication reported that only about 11% of adults with ADHD received treatment for the disorder within the past 12 months. These data reinforce the ongoing need to educate clinicians concerning the recognition and treatment of ADHD in childhood, adolescence, and adulthood. This enduring On-Demand activity will discuss the diagnosis and treatment of ADHD, with particular emphasis on the period from early adolescence to adulthood, through didactic presentation and case vignettes, and will reinforce clinical knowledge for those who attended an evening symposium, while providing a focused educational experience for first-time participants.